BRASILIA (Reuters) – Brazilian health regulator Anvisa on Friday approved a request by biochemical institute Fiocruz to import more doses of the vaccine developed by AstraZeneca and Oxford University from the Serum Institute of India, without specifies how many.
Also on Friday, Fiocruz said in a statement, not to mention Anvisa’s agreement, that they were negotiating an import of an additional 2 million doses from the Serum Institute, in addition to the 2 million agreed as- Yes.
So far Brazil, which is in the midst of the world’s second most lethal outbreak of COVID-19 after the United States, is only an authorized AstraZeneca vaccine and another developed by SinoVac in China for emergency use.
Reciting with Ricardo Brito; Written by Jake Spring and Aurora Ellis